Prof. Xiangdong Cheng 程向东
Chief Physician, Professor
Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of digestive system tumors, with a focus on gastric cancer. Expertise includes open and laparoscopic radical gastrectomy, Whipple procedure, and surgical management of peritoneal metastasis.
Dr. Cheng holds a medical doctorate from Germany and serves as Professor and Chief Physician. Dr. Cheng developed the Kissing pancreaticojejunostomy to reduce post-Whipple complications and introduced specific lymph node dissection techniques. Research includes advanced gastric cancer conversion therapy, with data from the CONVO-GC-1 study. Dr. Cheng has published over 70 papers, including 30 SCI articles, and leads national clinical collaboration projects.
Professional roles
- Director, Zhejiang Cancer Center
- Vice Chair, Gastric Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Oncologic Surgeons Committee, Chinese Medical Doctor Association
- Chair, Gastric Tumor Professional Committee, Zhejiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Cheng Xiangdong). Papers usually list the name as Xiangdong Cheng or Cheng X.
Selected publications
198 papers on PubMed matched by name and affiliation; 102 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gut, 2026 (senior author): Multisite metastatic atlas of gastric cancer identifies C/EBPβ as a regulator promoting liver metastasis. PubMed 42901757
- Crit Rev Oncol Hematol, 2026 (senior author): Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy. PubMed 42398683
- Cancer Res, 2026 (senior author): PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance. PubMed 42314057
- Nano Lett, 2026 (senior author): Zwitterionic Brush-Engineered Molecular Spherical Nucleic Acids for Enhanced Intracellular Antisense Activity. PubMed 42715048
- Lancet Oncol, 2026 (senior author): Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRAS(G12C) mutation: a multicentre, randomised, phase 1b/2 trial. PubMed 42636835
- Cancer Cell, 2026 (senior author): Perioperative tislelizumab plus chemotherapy for locally advanced gastric cancer: A randomized, prospective phase 2 trial. PubMed 42456653
- Ann Surg Oncol, 2026 (senior author): Impact of Neoadjuvant Chemotherapy on Prognosis of Patients with Mucinous Gastric Adenocarcinoma: A Propensity Score Matching Study. PubMed 42036601
- Discov Oncol, 2026 (senior author): Adipocytes in cancer a metabolic paradox and the dawn of novel therapeutics. PubMed 42380683
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion